Alteogen merges subsidiary Alteogen Biologics into parent in absorption deal

• Alteogen set to absorb wholly owned subsidiary Alteogen Biologics in a merger to integrate R&D, manufacturing, clinical, regulatory activities.
• Deal implies a merger ratio of 1:0.1679581, valuing Alteogen shares at 261,345 won, Alteogen Biologics at 43,895 won.
• Transaction to issue 600,477 new common shares; merger date set for Dec. 29, 2026.
• Shareholder vote scheduled for Nov. 27, 2026; creditor objection period runs Nov. 27 to Dec. 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alteogen Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006900744), on October 06, 2026, and is solely responsible for the information contained therein.